Journal of clinical gastroenterology最新文献

{"title":"Overuse of Intravenous Proton-Pump Inhibitors in the Treatment of Low-Risk Upper Gastrointestinal Bleeding.","authors":"Michael M Sutton, Mathew J Gregoski, Don C Rockey","doi":"10.1097/MCG.0000000000002211","DOIUrl":"https://doi.org/10.1097/MCG.0000000000002211","url":null,"abstract":"<p><strong>Background: </strong>In patients with acute upper GI bleeding (UGIB), current best practice is to discontinue or transition (to oral) intravenous proton pump inhibitors (PPIs) when esophagogastroduodenoscopy (EGD) reveals low risk or no peptic ulcer disease (PUD).</p><p><strong>Study: </strong>This retrospective study from a large academic medical center evaluated the use of intravenous PPIs in patients admitted with acute UGIB due to low-risk PUD or non-PUD UGIB. Complete clinical data including endoscopic lesions and the duration of intravenous PPI therapy were recorded.</p><p><strong>Results: </strong>Of 335 patients with acute UGIB, 253 had no PUD or an ulcer with only low-risk stigmata; 79 patients [31% (95% CI: 26%-37%)] received the appropriate duration of IV PPI. For patients with low-risk PUD (n=42), patients received on average 5.3 excess doses of intravenous PPI, and patients receiving continuous intravenous PPI received an average of 41 additional hours of IV PPI. Likewise, excess PPI therapy was common for patients found to have no lesions or no PUD. Lesions most often associated with inappropriate IV PPI use included: no identifiable lesion (n=59; 34%), low-risk PUD (n=42; 24%), gastritis (n=31; 18%), esophagitis (n=24, 14%), and AVMs (n=21, 12%). The length of hospital stay was shorter in patients who received appropriate PPI therapy after EGD compared with those who did not (4.3 vs. 7.2 d, P=0.001).</p><p><strong>Conclusions: </strong>IV PPIs are grossly overused in patients with UGIB, suggesting that there is substantial room for improvement in the use of PPIs in patients with acute UGIB.</p>","PeriodicalId":15457,"journal":{"name":"Journal of clinical gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in Urban-rural Disparities in Hepatocellular Carcinoma Mortality in the United States From 1999 to 2020.","authors":"Chun-Wei Pan, Pojaskorn Danpanichkul, Ramsey Cheung, Paulo Pinheiro, Patricia D Jones, Robert J Wong","doi":"10.1097/MCG.0000000000002162","DOIUrl":"https://doi.org/10.1097/MCG.0000000000002162","url":null,"abstract":"<p><strong>Objective: </strong>Hepatocellular carcinoma (HCC) is a growing public health concern in the United States. While socioeconomic factors have been linked to HCC outcomes, the impact of urban-rural residence remains understudied. This analysis examines trends in HCC mortality between urban and rural areas from 1999 to 2020.</p><p><strong>Materials and methods: </strong>Using the \"Centers for Disease Control and Prevention Wide Ranging Online Data for Epidemiologic Research\" database, we analyzed age-adjusted HCC mortality rates in urban and rural counties. Joinpoint regression was used to calculate annual percentage change and average annual percentage change (AAPC) in mortality rates. We examined trends by demographics and geographic regions.</p><p><strong>Results: </strong>Overall HCC mortality increased from 1999 to 2020 (AAPC: 1.24%). Rural areas experienced a more rapid rise (AAPC: 1.97%) in HCC mortality compared with urban areas (AAPC: 1.11%), and in 2020 HCC mortality in rural areas surpassed that in urban areas. Significant disparities in HCC mortality were also observed by other sociodemographic factors, with the highest HCC mortality among men, older adults, and ethnic minority populations in rural regions.</p><p><strong>Conclusion: </strong>Significant disparities in HCC mortality were observed by urban-rural geography in the United States, which seems to be exacerbated by underlying sociodemographic factors. Better understanding of potential modifiable drivers of these disparities will help guide interventions to improve long-term patient outcomes.</p>","PeriodicalId":15457,"journal":{"name":"Journal of clinical gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medications for Weight Loss and MASLD: A National Survey of Hepatology and Gastroenterology Provider Practices, Attitudes, and Knowledge Before Resmetirom.","authors":"Gene Y Im, Amon Asgharpour, Elizabeth S Aby, Jonathan G Stine, Jessica L Mellinger, Jay Luther, Manhal Izzy, Lamia Haque, Brian T Lee, Thomas G Cotter, Courtney B Sherman, Loretta L Jophlin, Aparna Goel, John Rice, Shaun Chandna, Blanca Lizaola-Mayo, Po-Hung Chen, Ashwani K Singal, Meena B Bansal","doi":"10.1097/MCG.0000000000002147","DOIUrl":"10.1097/MCG.0000000000002147","url":null,"abstract":"<p><strong>Goals: </strong>Our aim was to perform a national survey of provider attitudes, practices, and knowledge regarding weight loss and MASLD medications in patients with MASLD.</p><p><strong>Background: </strong>While weight loss is a cornerstone in the management of metabolic dysfunction-associated steatotic liver disease (MASLD), FDA-approved medications for weight loss remain underutilized.</p><p><strong>Results: </strong>We conducted a survey before resmetirom approval of hepatology and gastroenterology providers practicing in 44 states. Surveys were sent to 747 providers with 304 complete responses (41%), of whom 260 (86%) work at a liver transplant center. While nearly all respondents (96%) believed that weight loss medications could benefit patients with MASLD, 77% have never/rarely prescribed them due to low comfort (81%). Among weight loss medication prescribers, glucagon-like peptide-1 (GLP-1) receptor agonists were preferred (66%). In contrast, 63% had prescribed off-label medications for MASLD in the past 12 months, most commonly vitamin E (30%) and GLP-1 receptor agonists (25%). The top reported barriers to prescribing weight loss medications were lack of training/unfamiliarity, cost/insurance coverage, and side-effects, which may be explained by low formal obesity education and lack of knowledge (only 33% of FDA-approved medications for weight loss were correctly identified by >50% of providers). Overall, there was reasonable provider-reported adherence to the 2023 AASLD practice guidance for MASLD.</p><p><strong>Conclusions: </strong>This nationwide survey of hepatology and gastroenterology providers before resmetirom demonstrates that while off-label prescribing for MASLD was common, weight loss medication prescription rates remain very low due to low comfort possibly from insufficient education despite strong beliefs that they can benefit patients with MASLD.</p>","PeriodicalId":15457,"journal":{"name":"Journal of clinical gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Performance, Efficacy, and Safety of Lubiprostone in Bowel Preparation Regimens: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","authors":"Yizhong Wu, Joseph Gung, Kyle S Liu, Alexander D Grieme, Manuel Garza, Daryl Ramai, Aline Ghaleb, Andrew Han","doi":"10.1097/MCG.0000000000002215","DOIUrl":"10.1097/MCG.0000000000002215","url":null,"abstract":"<p><strong>Introduction: </strong>Bowel preparation is an essential part of the colonoscopy process, with inadequate or poor bowel preparation associated with decreased polyp detection. We performed a systematic review and meta-analysis to investigate the effects of adjunct lubiprostone bowel prep on colonoscopies performance.</p><p><strong>Methods: </strong>We conducted a comprehensive search in PubMed, Embase, Cochrane, and Web of Science from inception until February 2025 for RCTs comparing lubiprostone adjunct therapy, bowel prep and control. Our data was analyzed for polyp detection rates, bowel prep quality, colonoscopy duration, adverse events, and side effects. A random effects model was used, and the data were presented using pooled odds ratios (OR) and mean differences (MD) with 95% CI.</p><p><strong>Results: </strong>Eight RCT manuscripts were included with 1322 patients (657 in the lubiprostone group and 665 in the control group). There was no significant difference in polyp detection rate between groups (OR: 1.27, 95% CI: 0.92-1.76, P =0.15, I2 : 0%). The lubiprostone group had significantly higher odds of excellent bowel prep compared with control (OR: 2.25, 95% CI: 1.52-3.33, P <0.0001, I2 : 41%) and significantly lower odds of poor bowel prep ( P =0.009). Colonoscopy duration in minutes was similar ( P =0.17). Adverse event odds were similar between groups ( P =0.22).</p><p><strong>Conclusion: </strong>Lubiprostone as an adjunct agent for bowel prep improves the odds of excellent quality prep while mitigating the odds of poor prep. Lubiprostone adjunct bowel prep is similar to control in adverse effects.</p>","PeriodicalId":15457,"journal":{"name":"Journal of clinical gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Clinical Effectiveness and Safety of Vedolizumab and Ustekinumab in Biologic-Naive Patients With Crohn's Disease By Disease Location: Results from the EVOLVE Expansion Study.","authors":"Michael Scharl, Britt Christensen, Brian Bressler, Neil R Brett, Lauren Gianchetti, Celine Gisler, Pravin Kamble, Shashi Adsul, Zeinab Farhat, Marc Ferrante","doi":"10.1097/MCG.0000000000002186","DOIUrl":"https://doi.org/10.1097/MCG.0000000000002186","url":null,"abstract":"<p><strong>Goals: </strong>This analysis compared the real-world effectiveness and safety of vedolizumab versus ustekinumab in biologic-naive patients by CD location.</p><p><strong>Background: </strong>Crohn's disease (CD) location may affect disease course and treatment decisions.</p><p><strong>Study: </strong>Medical charts of biologic-naive patients with CD aged 18 years or older initiating vedolizumab or ustekinumab were analyzed in the multicenter, observational, retrospective EVOLVE Expansion study. Outcomes with vedolizumab versus ustekinumab over 36 months were compared in patients with baseline isolated ileal, ileocolonic, and isolated colonic CD (Montreal classification).</p><p><strong>Results: </strong>This analysis included 293 patients with ileal (vedolizumab, n=158, ustekinumab, n=135), 185 with ileocolonic (vedolizumab, n=91, ustekinumab, n=94), and 121 with colonic (vedolizumab, n=84, ustekinumab, n=37) CD. Cumulative rates over 36 months were similar between vedolizumab and ustekinumab in ileal, ileocolonic, and colonic CD subgroups for clinical response, remission, mucosal healing, and treatment persistence. There were no differences in risks of serious adverse events, serious infections, CD exacerbations, and CD-related hospitalizations between cohorts across disease location; the risk of CD-related surgeries was similar in patients with ileocolonic and colonic CD, and higher with vedolizumab versus ustekinumab in patients with ileal CD. CD-related surgeries for ileal CD were reported in 12 of 158 (7.6%) vedolizumab-treated patients and 3 of 135 (2.2%) ustekinumab-treated patients.</p><p><strong>Conclusions: </strong>Effectiveness, safety, and health care resource utilization outcomes over 36 months were similar between treatment cohorts regardless of baseline disease location. The number of patients requiring CD-related surgeries was low. Both vedolizumab and ustekinumab can be used as first-line biologics in patients with CD, regardless of disease location.</p>","PeriodicalId":15457,"journal":{"name":"Journal of clinical gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144484504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biological Therapies in Inflammatory Bowel Disease: Predictive Factors of Nonresponse.","authors":"Teresa Da Cunha, Rachael Hagen, Haleh Vaziri","doi":"10.1097/MCG.0000000000002179","DOIUrl":"https://doi.org/10.1097/MCG.0000000000002179","url":null,"abstract":"<p><p>The treatment modalities for inflammatory bowel disease (IBD) have been rapidly expanding over the past years. Biological therapies are the leading choice of therapy in moderate and severe IBD, aiming to help patients achieve meaningful clinical, endoscopic, and laboratory responses. However, some patients are primary nonresponders and fail to show any response, while others relapse after an initial response, also known as secondary nonresponders. In this article, we review the mechanism of action of the currently available biological therapies for IBD, assessment of treatment response, the nonresponse rates to each therapy, clinical and laboratory factors affecting the efficacy of therapies, and suggested targeted drug levels.</p>","PeriodicalId":15457,"journal":{"name":"Journal of clinical gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Safety and Efficacy of Colorectal Endoscopic Submucosal Dissection in the Elderly: A Large Western Analysis of 710 Lesions.","authors":"Fares Ayoub, Mai Khalaf, Samanthika Sahasra Devalaraju, Tara Keihanian, Wasseem Skef, Salmaan Jawaid, Mohamed Othman","doi":"10.1097/MCG.0000000000002213","DOIUrl":"https://doi.org/10.1097/MCG.0000000000002213","url":null,"abstract":"<p><strong>Background and study aims: </strong>Colorectal endoscopic submucosal dissection (ESD) is increasingly used for the management of laterally spreading colorectal lesions in the West. With increasing life expectancy and prevalence of colorectal neoplasia, ESD is frequently performed in the elderly. While ESD has been shown to be safe in elderly Eastern populations, there are key differences in endoscopist, patient, and lesion characteristics in the West. We investigated the safety and outcomes of colorectal ESD in a large Western cohort.</p><p><strong>Patients and methods: </strong>We retrospectively analyzed 710 colorectal lesions undergoing ESD at a tertiary medical center from July 2015 to November 2024. Patients were divided into 3 age groups: under 65 years (n=342), 65 to 75 years (n=272), and older than 75 years (n=96). Outcomes included en-bloc and R0 resection rates, procedural and postprocedural adverse events, and length of stay.</p><p><strong>Results: </strong>En-bloc resection rates (87.4%, 80.9%, and 80.2%) and R0 resection rates (69.6%, 68%, and 61.5%) were comparable across the <65, 65 to 75, and ≥75 groups, respectively. Despite higher comorbidities and use of antithrombotics/anticoagulants in the elderly group, overall postprocedure adverse event rates were low and with no significant difference among groups (6.7%, 8.5%, and 6.3%) (P=0.651). A higher length of stay in the ≥75 group was noted compared with the <65, 65 to 75, respectively (1.1 d, vs. 0.6 and 0.5, P<0.001).</p><p><strong>Conclusions: </strong>Colorectal ESD in Western elderly patients by expert endoscopists is safe and effective, with outcomes comparable to younger cohorts. This study supports ESD as a feasible option for managing colorectal neoplasms in an aging population.</p>","PeriodicalId":15457,"journal":{"name":"Journal of clinical gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Gastroenterologist's Approach to Improving Metabolic Health in MASLD.","authors":"Eyad Abdulrazzak, Imad Alabdul Razzak, Mazen Noureddin, Hirsh D Trivedi","doi":"10.1097/MCG.0000000000002210","DOIUrl":"https://doi.org/10.1097/MCG.0000000000002210","url":null,"abstract":"<p><p>Gastroenterologists are often the first to encounter patients with metabolic dysfunction-associated steatotic liver disease (MASLD), the most common chronic liver disease worldwide. While MASLD can lead to cirrhosis and hepatocellular carcinoma, cardiovascular disease (CVD) remains the leading cause of mortality in this population. This heightened risk is largely driven by the strong association between MASLD and CVD risk factors, including type 2 diabetes, obesity, and hypertension. Therefore, addressing metabolic health is a fundamental component of MASLD management. Gastroenterologists play a key role in identifying metabolic risk factors, recommending lifestyle, and pharmacologic interventions, in consultation with specialists or multidisciplinary care teams when appropriate. This review provides a practical framework for integrating metabolic health optimization into routine MASLD care, equipping gastroenterologists with the necessary tools to improve both liver-related and overall patient outcomes.</p>","PeriodicalId":15457,"journal":{"name":"Journal of clinical gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of Esophageal Ulcers Using the Japanese Adverse Drug Event Report Database.","authors":"Teruaki Hayashi, Kazumasa Kotake, Miyu Fujioka, Kenta Yamaoka, Tadashi Shimizu","doi":"10.1097/MCG.0000000000002212","DOIUrl":"https://doi.org/10.1097/MCG.0000000000002212","url":null,"abstract":"<p><strong>Goals: </strong>Identifying oral and parenteral drugs associated with esophageal ulcers is important. A comprehensive analysis of a spontaneous adverse event reporting database can support early detection and prevention of drug-induced esophageal ulcers.</p><p><strong>Background: </strong>Drug-induced esophageal ulcers are primarily associated with orally administered drugs. However, recent studies have suggested potential association with parenterally administered drugs. These parenteral cases have not been comprehensively analyzed in previous research.</p><p><strong>Study: </strong>We conducted disproportionality analysis using data from the Japanese Adverse Drug Event Report (JADER) database between April 2004 and December 2023. Signals for esophageal ulcers were detected using the reporting odds ratio with a 95% confidence interval. Weibull distribution analysis was performed to determine the time to adverse event onset for drugs showing signals of esophageal ulcers. Orally and parenterally administered drugs were analyzed separately.</p><p><strong>Results: </strong>Signals were detected for 15 orally administered drugs and 7 parenterally administered anticancer drugs. Weibull distribution analysis revealed that doxycycline and dabigatran etexilate induced the early onset of pill-induced esophagitis, with median onset times of 8 and 12.5 days. Meanwhile, bevacizumab and paclitaxel showed consistent occurrence patterns of esophageal ulcers throughout the treatment period.</p><p><strong>Conclusions: </strong>Our comprehensive analysis of the JADER database identified signals for esophageal ulcers associated with both oral and parenteral drugs, along with their characteristic onset patterns. These findings highlight the clinical importance of considering the potential for esophageal ulcers with specific oral and parenteral drugs and suggest that early intervention may be crucial in mitigating their occurrence.</p>","PeriodicalId":15457,"journal":{"name":"Journal of clinical gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Liver Cirrhosis Patients Hospitalized for Influenza Compared With COVID-19 Between 2020 and 2021 in the United States.","authors":"Renuka Verma, Kamleshun Ramphul, Kyaw M Tun, Yasmeen Obeidat, Lily Liu, Hemamalini Sakthivel, Tejas Joshi","doi":"10.1097/MCG.0000000000002199","DOIUrl":"https://doi.org/10.1097/MCG.0000000000002199","url":null,"abstract":"<p><strong>Background: </strong>Early studies during the COVID-19 pandemic showed that liver cirrhosis patients were at risk of more severe outcomes of the disease. Past studies have also linked cirrhosis patients with poorer influenza outcomes following admissions.</p><p><strong>Aim: </strong>To compare how patients with liver cirrhosis fared when admitted for COVID-19 as compared with influenza in the United States.</p><p><strong>Methods: </strong>The National Inpatient Sample (NIS) from 2016 to 2021 was used. The influenza group of cirrhosis patients was extracted for admissions between 2016 and 2019, while the COVID-19 group involved hospitalizations in 2020 and 2021. Baseline characteristics and differences in outcomes were compared between cirrhosis patients with COVID-19 versus influenza.</p><p><strong>Results: </strong>We recruited 59,590 cirrhosis patients, among whom 6800 (11.4%) had influenza and 52790 (88.6%) were infected with COVID-19. COVID-19 cases were younger, with more patients having dyslipidemia, diabetes, chronic kidney disease (CKD), obesity, and dementia, but fewer patients were smokers, peripheral vascular disease (PVD), history of stroke, history of myocardial infarction, drug abuse, alcohol abuse, chronic ischemic heart disease (IHD), asthma, COPD, and cancer. Our propensity-score matched sample had 6670 cases with COVID-19 and 6670 with influenza. COVID-19 patients were more likely to suffer from hyponatremia, acute myocardial infarction, cardiogenic shock, severe septic shock, mechanical ventilation use, prolonged mechanical ventilation use, cardiac arrest, acute ischemic stroke, acute kidney injury, and all-cause death, but fewer cases with ascites, and hepatorenal syndrome.</p><p><strong>Conclusions: </strong>The characteristics of cirrhosis patients admitted with COVID-19 differed from those admitted for influenza, with COVID-19 showing a higher mortality risk and varying differences in other complications.</p>","PeriodicalId":15457,"journal":{"name":"Journal of clinical gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}